Reviewing PLx Pharma Inc. (PLXP)’s and Epizyme Inc. (NASDAQ:EPZM)’s results

PLx Pharma Inc. (NASDAQ:PLXP) and Epizyme Inc. (NASDAQ:EPZM) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
PLx Pharma Inc. 6 48.16 N/A -3.17 0.00
Epizyme Inc. 13 46.35 N/A -1.64 0.00

Table 1 showcases the top-line revenue, earnings per share and valuation of PLx Pharma Inc. and Epizyme Inc.

Profitability

Table 2 shows the return on equity, net margins and return on assets of the two firms.

Net Margins Return on Equity Return on Assets
PLx Pharma Inc. 0.00% -929.7% -122.2%
Epizyme Inc. 0.00% -51.8% -43.1%

Risk and Volatility

A 5.1 beta means PLx Pharma Inc.’s volatility is 410.00% more than S&P 500’s volatility. Competitively, Epizyme Inc.’s beta is 2.46 which is 146.00% more volatile than S&P 500.

Analyst Recommendations

The table given features the ratings and recommendations for PLx Pharma Inc. and Epizyme Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
PLx Pharma Inc. 0 0 0 0.00
Epizyme Inc. 0 0 2 3.00

Competitively Epizyme Inc. has a consensus target price of $21.5, with potential upside of 79.77%.

Institutional and Insider Ownership

The shares of both PLx Pharma Inc. and Epizyme Inc. are owned by institutional investors at 22% and 94.5% respectively. 2.2% are PLx Pharma Inc.’s share owned by insiders. On the other hand, insiders owned about 0.2% of Epizyme Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
PLx Pharma Inc. -4.23% -14.9% 11.63% 17.72% 56.27% 299.35%
Epizyme Inc. -2.64% 2.31% 10.32% 30.26% 7.8% 115.26%

For the past year PLx Pharma Inc.’s stock price has bigger growth than Epizyme Inc.

Summary

On 6 of the 8 factors Epizyme Inc. beats PLx Pharma Inc.

PLx Pharma Inc., a late-stage specialty pharmaceutical company, focuses on developing nonsteroidal anti-inflammatory drugs and other pharmaceutical agents. Its lead product is Aspertec 325 mg, a novel formulation of aspirin that uses the PLxGuard delivery system to reduce acute gastrointestinal (GI) side effects while providing antiplatelet effectiveness for cardiovascular disease prevention. The companyÂ’s product pipeline also includes other oral nonsteroidal anti-inflammatory drugs using the PLxGuard delivery system, including PL1200 Ibuprofen 200 mg, a clinical-stage GI-safer ibuprofen product for pain and inflammation; and Aspertec 81 mg, a novel formulation of aspirin, which is in late-stage development. The company was founded in 2002 and is headquartered in Houston, Texas.

Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops novel epigenetic therapies for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2 HMT, which is in five-arm Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II and Ib clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial for elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function, as well as Phase II clinical trial in adult patients with ovarian cancer. The company is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias; and PRMT5 inhibitor that is in Phase I clinical trial for patients with solid tumors and NHL. It has collaboration agreements with Celgene Corporation, Celgene RIVOT Ltd., Genentech Inc., Glaxo Group Limited, and US Oncology Research, as well as with Roche Molecular Systems, Inc., Eisai Co. Ltd., and Lymphoma Study Association. Epizyme, Inc. was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.